New drug combo takes aim at KRAS-Mutant lung cancer

NCT ID NCT07562581

Not yet recruiting Disease control Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether combining two oral drugs, luvometinib and anlotinib, can shrink tumors in people with KRAS-mutated non-small cell lung cancer that has spread and stopped responding to prior treatment. About 48 adults will receive different dose combinations. The main goal is to see how many patients have their tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luvometinib and anlotinib (two cancer drugs taken as pills)
What this could lead to: If successful, this combination could offer a new treatment option for people with a hard-to-treat form of lung cancer that has spread.
What could go wrong: This is an early Phase 2 study with only 48 people, so results are preliminary. The drugs may cause side effects and may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS-MUTATED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS-MUTATED METASTASIS NON-SMALL CELL LUNG CANER PREVIOUS TREAMTED

Contacts and locations

Locations

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.